Peter Attia's Three-Question Framework for Cutting Through Supplement Noise

Most supplement decisions are made backwards: someone encounters a plausible mechanism, reads two positive studies, and starts taking it. Peter Attia’s AMA #85 is a direct attempt to reverse that sequence with a structured evaluation framework.

The Problem With How Most People Evaluate Supplements

Before any supplement or medication analysis, Attia argues, most people skip the most important step: defining the problem they’re actually trying to solve. Not “I want to improve my health” or “I want more energy”—something specific. A measurable metric, a target threshold, a realistic timeframe. The example he uses: not “my cholesterol is bad,” but “my ApoB is 130 mg/dL and I want it below 60 within six months.”

The reason precision matters is that vague goals guarantee false positives. When the target is undefined, almost any result looks like evidence of success. A slightly better day, one improved lab value, or a single good night’s sleep becomes proof that the supplement works. This is how people end up taking supplements for years with no real evidence of benefit—they were never tracking the right thing to begin with.

Attia’s framing is direct: “Poor problem definition almost guarantees some sort of false positive.”

The Three-Question Framework

Attia structures supplement and medication evaluation around three sequential questions:

Define your objective precisely. What specific condition, metric, or symptom are you addressing? Specificity prevents the false positive trap. A vague objective will find confirming evidence regardless of whether anything is actually working.

Identify your biomarker. How will you know if it’s working? This must be a measurable signal—a lab value, a tracked metric, a functional improvement—not a subjective impression. Without measurement, evaluation is guesswork.

Weigh risk against reward honestly. This isn’t just side effects. It includes cost, inconvenience, and the opportunity cost of taking something that isn’t working. Understanding mechanism, patient-year data, and both short and long-term risks is part of this calculus. Attia also asks: what happens if you do nothing? If the condition doesn’t meaningfully increase disease risk or reduce quality of life, intervention may be unnecessary.

Why Evidence Standards Depend on Intent

The framework’s most useful distinction is between preventive and treatment interventions. Preventive interventions taken by healthy people require stronger evidence because baseline risk is low—the absolute benefit must clearly outweigh even small risks. Treatment interventions for existing conditions can justify lower evidence standards because the condition itself already poses risk.

This distinction collapses in most supplement discussions. A study showing modest benefit in people with a specific deficiency gets applied broadly to healthy populations without that deficiency. The evidence bar for “should a healthy person take this preventively” is substantially different from “does this help someone who already has the problem.”

Mechanistic reasoning doesn’t clear the bar either. A supplement with a plausible biological pathway doesn’t become worth taking without evidence it works in real humans. The pathway from “this should work” to “this actually works” requires evidence, not speculation.

The FDA distinction between supplements and medications matters here. Supplements aren’t pre-approved for safety or efficacy. Quality control is inconsistent. The regulatory gap means supplements deserve more skepticism, not less—despite how they’re marketed relative to pharmaceuticals.

Source: Peter Attia MD

Content created with AI assistance and reviewed for accuracy.